Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells - PubMed (original) (raw)
Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells
Ivana Cecic et al. Photochem Photobiol. 2006 Mar-Apr.
Abstract
Tumor treatment by photodynamic therapy (PDT) provokes a host-protective inflammatory and acute-phase response and an immune reaction. Neutrophilia manifested in this context is driven by multiple mediators of neutrophil chemotaxis orchestrated by an activated complement system. Mouse FsaR fibrosarcoma was used in this study to further investigate neutrophilia induced by Photofrin-based PDT. The complement anaphylatoxin C3a was identified as a major chemoattractant in the advanced phase of PDT-induced neutrophilia, because injecting mice with antibodies blocking its receptor C3aR significantly inhibited the increase in neutrophil levels 8 h after PDT. At the same time point, an increased C3aR expression was detected in neutrophils, monocytes and B lymphocytes in the blood of host mice. Peritoneal macrophages and mast cells harvested from treatment-naive mice exhibited elevated C3aR expression after coincubation in vitro for 8 h with PDT-treated FsaR cells. Thus, C3a emerges as one of the key effector molecules engaged in PDT-induced host response.
Similar articles
- Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy.
Cecic I, Stott B, Korbelik M. Cecic I, et al. Int Immunopharmacol. 2006 Aug;6(8):1259-66. doi: 10.1016/j.intimp.2006.03.008. Epub 2006 Apr 19. Int Immunopharmacol. 2006. PMID: 16782538 - PDT-associated host response and its role in the therapy outcome.
Korbelik M. Korbelik M. Lasers Surg Med. 2006 Jun;38(5):500-8. doi: 10.1002/lsm.20337. Lasers Surg Med. 2006. PMID: 16634073 Review. - The role of the complement anaphylatoxins in the recruitment of eosinophils.
DiScipio RG, Schraufstatter IU. DiScipio RG, et al. Int Immunopharmacol. 2007 Dec 20;7(14):1909-23. doi: 10.1016/j.intimp.2007.07.006. Epub 2007 Aug 6. Int Immunopharmacol. 2007. PMID: 18039528 Review.
Cited by
- Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better.
Thiruppathi J, Vijayan V, Park IK, Lee SE, Rhee JH. Thiruppathi J, et al. Front Immunol. 2024 Apr 5;15:1375767. doi: 10.3389/fimmu.2024.1375767. eCollection 2024. Front Immunol. 2024. PMID: 38646546 Free PMC article. Review. - Antitumor Immunity Mediated by Photodynamic Therapy Using Injectable Chitosan Hydrogels for Intratumoral and Sustained Drug Delivery.
Gierlich P, Donohoe C, Behan K, Kelly DJ, Senge MO, Gomes-da-Silva LC. Gierlich P, et al. Biomacromolecules. 2024 Jan 8;25(1):24-42. doi: 10.1021/acs.biomac.3c00591. Epub 2023 Oct 27. Biomacromolecules. 2024. PMID: 37890872 Free PMC article. - Multifunctional Nanosystems Powered Photodynamic Immunotherapy.
Ma Y, Xiao F, Lu C, Wen L. Ma Y, et al. Front Pharmacol. 2022 May 11;13:905078. doi: 10.3389/fphar.2022.905078. eCollection 2022. Front Pharmacol. 2022. PMID: 35645842 Free PMC article. Review. - Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.
Asadzadeh Z, Safarzadeh E, Safaei S, Baradaran A, Mohammadi A, Hajiasgharzadeh K, Derakhshani A, Argentiero A, Silvestris N, Baradaran B. Asadzadeh Z, et al. Cancers (Basel). 2020 Apr 23;12(4):1047. doi: 10.3390/cancers12041047. Cancers (Basel). 2020. PMID: 32340275 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources